Skip to main content
SpringerLink
Log in

Psychopharmacology

Pharmacodynamic Approach

  • Chapter
Psychiatry for Neurologists

Part of the book series: Current Clinical Neurology ((CCNEU))

  • 1403 Accesses

Abstract

The modern era of psychotropic medications has supplied providers and patients with substantial ammunition in the treatment of psychiatric disorders. Despite the variety of psychotropic medications available for the treatment of common psychiatric conditions, room for improvement exists. Antipsychotics, antidepressants, and anxiolytics with enhanced efficacy, refined pharmacological profiles, and reduced side effects would be welcomed. In addition to improvements in the pharmacological treatment of the most common psychiatric disorders, pharmacological treatment of other psychiatric illnesses should be enhanced. Psychotropic medications are commonly used for many disorders besides schizophrenia, depression, bipolar disorder, and anxiety disorder. The prescription of antipsychotics for aggression associated with dementia and anxiolytics for sleep disturbances are examples. Medications not classically considered to be psychotropics are also used for psychiatric conditions (e.g., anticonvulsant medications for mood stabilization). This diverse use of medications with psychotropic properties, both indicated and off-label, is accompanied by evidence that varies widely in terms of its quality and quantity of support. All of these factors can create confusing therapeutic situations for psychiatrists and nonpsychiatrists when prescribing psychotropic medications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ketter TA, Wang PW, Becker OV, Nowakowska C, Yang Y. The diverse roles of anticonvulsants in bipolar disorders. Ann Clin Psychiatry. 2003;15:95–108.

    Article  PubMed  Google Scholar 

  2. Krystal JH, Sanacora G, Blumberg G, et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry. 2002;7(Suppl 1):S71–S80.

    Article  PubMed  CAS  Google Scholar 

  3. Stahl SM. Tiagabine and other anticonvulsants with action on GABA. J Clin Psychiatry 2004;65:291–292.

    PubMed  Google Scholar 

  4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, revision. Washington DC: American Psychiatric Association; 2000.

    Google Scholar 

  5. Arana GW, Rosenbaum JF. Handbook of Psychiatric Drug Therapy, Fourth Edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2000.

    Google Scholar 

  6. Katzung BG. Basic and Clinical Pharmacology, Ninth Edition. New York: McGraw-Hill; 2003.

    Google Scholar 

  7. Evins AE. Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. J Clin Psychiatry 2003;64(Suppl 8):9–14.

    PubMed  CAS  Google Scholar 

  8. Stahl SM, Muntner N. Essential Psychopharmacology, Second Edition. New York: Cambridge University Press; 2000.

    Google Scholar 

  9. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47:27–38.

    PubMed  Google Scholar 

  10. Gründer G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications. Arch Gen Psychiatry 2003;60:974–977.

    Article  PubMed  Google Scholar 

  11. Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R. Effects of psychotropic drugs on seizure threshold. Drug Saf 2002;25:91–110.

    Article  PubMed  CAS  Google Scholar 

  12. Baldessarini RJ. Current status of antidepressants: clinical pharmacology and therapy. J Clin Psychiatry 1989;50:117–126.

    PubMed  CAS  Google Scholar 

  13. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23–45.

    Article  PubMed  CAS  Google Scholar 

  14. Blanchet PJ. Antipsychotic drug-induced movement disorders. Can J Neurol Sci 2003;30(Suppl 1):S101–S107.

    PubMed  Google Scholar 

  15. Correll CU, Leucht S, Kane JM. Lower risk of tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161:414–425.

    Article  PubMed  Google Scholar 

  16. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992;18:701–715.

    PubMed  CAS  Google Scholar 

  17. Simpson GM. The treatment of tardive dyskinesia and tardive dystonia. J Clin Psychiatry 2000;61(Suppl 4):39–44.

    PubMed  CAS  Google Scholar 

  18. Hasan S, Buckley P. Novel antipsychotics and the neuroleptics malignant syndrome: a review and critique. Am J Psychiatry 1998;155:113–1116.

    Google Scholar 

  19. Fann JR. Neurological effects of psychopharmacological agents. Semin Clin Neuropsychiatry 2002;7:196–205.

    Article  PubMed  Google Scholar 

  20. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry 2002;14:175–182.

    Article  PubMed  Google Scholar 

  21. Lebovitz HE. Metabolic consequences of atypical antipsychotic drugs. Psychiatr Q 2003;74:277–290.

    Article  PubMed  Google Scholar 

  22. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002;14:59–64.

    Article  PubMed  Google Scholar 

  23. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596–601.

    Article  Google Scholar 

  24. Hubbard JR, Levenson JL, Graham PA. Psychiatric side effect associated with the ten most commonly dispensed prescription drugs: a review. J Fam Pract 1991;33:177–186.

    PubMed  CAS  Google Scholar 

  25. Levy S, Abaza MM, Hawkshaw MJ, Sataloff RT. Psychiatric manifestations of medications commonly prescribed in otolaryngology. Ear Nose Throat J 2001;80:266–271.

    PubMed  CAS  Google Scholar 

  26. Smith DA. Psychiatric side effects of non-psychiatric drugs. S D J Med 1991;44:291–292.

    PubMed  CAS  Google Scholar 

  27. Brown ES, Suppes T Khan DA, Carmody TJ. Mood changes during prednisone bursts in outpatients with asthma. J Clin Psychopharmacol 2002;22:55–61.

    Article  PubMed  Google Scholar 

  28. Brown ES, Khan DA, Nejtek VA. The psychiatric side effects of corticosteroids. Ann Allergy Asthma Immunol 1999;83:495–504.

    Article  PubMed  CAS  Google Scholar 

  29. Kershner P, Wang-Cheng R. Psychiatric side effects of steroid therapy. Psychosomatics 1989;30:135–139.

    PubMed  CAS  Google Scholar 

  30. Sternbach H, State R. Antibiotics: neuropsychiatric effects and psychotropic interactions. Harv Rev Psychiatry 1997;5:214–526.

    PubMed  CAS  Google Scholar 

  31. Hall CE, Keegan H, Rogstad KE. Psychiatric side effects of ofloxacin used in the treatment of pelvic inflammatory disease. Int J STD AIDS 2003;14:636–637.

    Article  PubMed  CAS  Google Scholar 

  32. Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanism, and future directions. J Clin Oncol 2000;18:2316–2326.

    PubMed  CAS  Google Scholar 

  33. Goeb JL, Cailleau A, Laine P, et al. Acute delirium, delusion, and depression during INF-beta-1a therapy for multiple sclerosis: a case report. Clin Neuropharmacol 2003;26:5–7.

    Article  PubMed  CAS  Google Scholar 

  34. Browning CH. Nonsteroidal anti-inflammatory drugs and severe psychiatric side effects. Int J Psychiatry Med 1996;26:25–34.

    Article  PubMed  CAS  Google Scholar 

  35. Clunie M, Crone L, Klassen L, Yip R. Psychiatric side effects of indomethacin in parturients. Can J Anesth 2003;50:586–588.

    Article  PubMed  Google Scholar 

  36. Saint-Cyr JA, Taylor AE, Lang AE. Neuropsychological and psychiatric side effects in the treatment of Parkinson’s disease. Neurology 1993;43(Suppl 6):S47–S52.

    PubMed  CAS  Google Scholar 

  37. Juethner SN, Seyfried W, Aberg JA. Tolerance of efavirenz-induced central nervous system side effects in HIV-infected individuals with a history of substance abuse. HIV Clin Trials 2003;4:145–149.

    Article  PubMed  Google Scholar 

  38. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15:71–75.

    Article  PubMed  CAS  Google Scholar 

  39. Wright JM, Sachdev PS, Perkins RJ, Rodriguez P. Zidovudine-related mania. Med J Aust 1989;150:339–341.

    PubMed  CAS  Google Scholar 

  40. Maxwell S, Scheftner WA, Kessler HA, Busch K. Manic syndrome associated with zidovudine treatment. JAMA 1988;259:3406–3407.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wingate University School of Pharmacy, Wingate, NC

    Christian Dolder PharmD

  2. Wingate University School of Pharmacy, Wingate, NC

    Beatriz Luna PharmD

Authors
  1. Christian Dolder PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Beatriz Luna PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Psychiatry and Neurosciences, University of California, San Diego

    Dilip V. Jests MD

  2. Department of Psychiatry and Neurosciences, VA San Diego Healthcare System, San Diego, CA

    Dilip V. Jests MD

  3. Parkinson’s Disease and Movement Disorders Center, NeuroHealth, Warwick, RI

    Joseph H. Friedman MD

  4. University Medical School, Providence, RI

    Joseph H. Friedman MD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Dolder, C., Luna, B. (2006). Psychopharmacology. In: Jests, D.V., Friedman, J.H. (eds) Psychiatry for Neurologists. Current Clinical Neurology. Humana Press. https://doi.org/10.1007/978-1-59259-960-8_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-960-8_24

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-483-8

  • Online ISBN: 978-1-59259-960-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation